bowel disease (IBD). We investigated the effects of an antibody against CD3 called otelixizumab, which induces immune tolerance, in intestinal mucosa samples from patients. Methods: Intestinal tissues were isolated from individuals undergoing routine endoscopy or from patients undergoing intestinal surgery for colon cancer or IBD;
Introduction
Since the first anti-CD3 antibody, muromonab (OKT3), was developed more than 30 years ago to prevent transplant rejection and graft versus host disease 1 , considerable progress has been made in the development and engineering of anti-CD3 antibodies for the treatment of immune disorders. OKT3 induces a cytokine storm, which obviates its use in the treatment of autoimmune conditions [2] [3] [4] . This cytokine storm is a consequence of the cross-linking of the CD3/T cell receptor (TcR) on T cells, coupled with Fc binding to the Fc gamma Receptor (FcR) on other immune cells. To reduce toxicity of anti-CD3 antibodies, F(ab) 2 fragments 5 and mutated, humanized Abs, which did not bind FcR, have been developed 6 . It is thought that these tolerising anti-CD3 antibodies function by driving the internalization of the TcR/CD3 complex so that signaling via peptide/MHC is abolished 7, 8 . In addition, the antibodies when binding to CD3/TcR may signal to the cell and drive differentiation along a tolerogenic pathway 7 .
Finally, there is some evidence that tolerising anti-T cell antibodies can cause T cell apoptosis 9 .
Tissue injury in inflammatory bowel disease is driven by T cells 10 and is therefore a disease target for T cell therapies. Initial studies in ulcerative colitis (UC) with the anti-CD3 antibody visilizumab showed clinical benefit 11, 12 , however, a randomized, placebocontrolled trial gave negative results 13 . In Crohn's disease (CD), a phase I study of the anti-CD3 antibody NI-0401 showed no improvement in Crohn's disease activity index, M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4 but there was significant endoscopic improvement 14 . Further clinical studies are clearly needed, however, what remains lacking is any evidence that anti-CD3 antibodies have an effect on pro-inflammatory T cells in the mucosa of patients with IBD.
Otelixizumab (TRX4 or ChAglyCD3), is an Fc-engineered, chimeric/humanized monoclonal IgG1 antibody against human CD3-epsilon which showed promising early results in Type I diabetes 15, 16 but was not superior to placebo in Phase 3 studies when given at a lower dose than the earlier work 17 . We have developed ex vivo assays where T cell activity in inflamed bowel tissue can be accurately studied [18] [19] [20] , and so we have 
Materials and Methods

Reagents and Antibodies
All reagents were purchased from Sigma Aldrich (Gillingham, UK) unless otherwise stated. Anti-human CD28 was purchased from R&D systems (Abingdon, UK).
Otelixizumab (Tolerx, Cambridge, MA, USA) is an aglycosylated chimeric/humanized monoclonal antibody (IgG1 lambda) directed against human CD3/epsilon (generously provided by GlaxoSmithKline). YTH12.5 is a mitogenic rat anti-human CD3 antibody (IgG2b lambda; provided by Tolerx) and the parental Ab of otelixizumab. Purified human IgG1 lambda was used for control purposes (Sigma Aldrich). IL-10 was neutralized with rat anti-IL-10 (used at 10μg/ml; BioLegend, Cambridge, UK).
Patient samples
Tissue was obtained during routine endoscopy or from surgical specimens of patients undergoing intestinal surgery because of colon cancer or IBD. Healthy intestinal tissue surrounding malignant tumors was sampled and used as control. All patients took part in this study after informed written consent. The study was approved by the local ethics committee. Patient characteristics are listed in supplementary table SI.
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Flow cytometry
Antibodies were used at the concentrations recommended by the manufacturer:
anti-CD4-FITC; anti-CD25-PE, CD2-APC, IFN-γ-PECy7, IL-10-PE, and matched isotype controls (BD Bioscience, Oxford, UK). PBS/20% human serum was used to block nonspecific binding and cell surface staining was performed for 30min on ice. For intracellular cytokine staining, cells were cultured overnight with otelixizumab or human IgG. For the last 4h of culture, 2 mM monensin was added. After surface staining, cells were fixed in Leucoperm (AbD Serotec, Oxford, UK) solution A, followed by permeabilization in solution B and intracellularly stained for 30min. Intracellular staining of Foxp3 was performed with the Alexa Fluor 647 anti-human Foxp3 flow kit from BioLegend (London, UK). Cell viability was assessed by annexin V-FITC and propidium iodide (PI) staining (BD Bioscience) as previously described 21 . For multi-colour flow cytometry, all analyses included the appropriate fluorescence-minus-one controls (i.e. samples stained with every reagent except for the one of interest to guide compensation. Flow cytometry was performed using the LSRII analyzer (Becton Dickinson), data were analyzed with FACS Diva software.
Quantification of CD3/TCR modulation by flow cytometry
PBMC (1x10 6 /mL) were cultured in RPMI + 10% AB serum in the presence or absence of otelixizumab. At indicated time points cells were removed, washed with FACS buffer (PBS + 1% FCS + sodium azide 0.1%) After Fc blocking for 5min with TruStain FcX 
Western blotting
Whole cell lysates were subjected to SDS-PAGE and immunoblotting as previously described 21 . Anti-T-bet (Santa Cruz, Heidelberg, Germany), anti-RORgt and anti-β-actin (Abcam, Cambridge, UK) were used according to manufacturer's instructions. Intensities of the protein bands were measured using Image J software and relative values were calculated by dividing the IgG and otelixizumab values by the untreated control.
Signaling arrays and cytokine arrays
Phosphorylation status of receptor tyrosine kinases and signaling molecules was determined by employing PathScan RTK signaling arrays (Cell Signaling, Danvers, MA, USA). Seventy-five μg protein of whole cell lysates were probed onto the array. Cytokine arrays were purchased from R&D Systems ("Proteome Profiler Cytokine array kit, Panel consistency and easier data presentation, the intensity values >1700 were given the same dark red colour. When otelixizumab reduced cytokines to undetectable levels, the fold reduction was given an arbitrary value of 10.
ELISA
Cytokine concentrations in culture supernatants were determined by enzyme linked immunosorbent assay (ELISA) using kits from R&D Systems (IL-17A), ImmunoTools (Friesoythe, Germany; IFN-γ) and ebioscience (Hatfield, UK; IL-2) according to manufacturer's instructions.
Quantitative real-time PCR
Tissue was sonicated in Trizol reagent (Life Technologies, Paisley, UK) and RNA isolated with the Direct-Zol kit (Zymo Research, Irvine, CA, USA). Reverse transcription was performed using QuantiTect Reverse Transcription Kit (Qiagen, Manchester, UK).
Quantitative RT-PCR was performed using QuantiFast SYBR Green PCR Kit (Qiagen) on a 7500 Real-Time PCR System (Applied Biosystems, Paisley, UK). IL-10 expression was determined as the geometric mean of IL10 normalized to GAPDH, RPL30 and PGK1 using the 2 -ΔCt method 24 . Primers: IL10 (QT00041685), PGK1 (QT00013776), RPL30 (QT00056651) (Qiagen). GAPDH: (forward) TGCACCACCAACTGCTTAGC; (reverse) GCATGGACTGTGGTCATGAG.
Statistical testing
Statistical analysis was performed with GraphPad Prism or InStat software. Twotailed Student t-test was used to compare two independent values and the One-way ANOVA with post-test was used for multiple comparisons. Array data were statistically M A N U S C R I P T
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10 analysed by calculating the average of all individual proteins in the individual groups and the sums of the resulting two data sets were then compared to each other with the Wilcoxon rank-sum test (in GraphPad Prism). For example, the intensity values of the individual cytokines in the group "CD treated with IgG" were averaged and the whole set of values then statistically compared to all cytokine averages in group "CD treated with otelixizumab". Tables used for calculations are shown in the supplementary material. A p value < 0.05 was considered significant.
Results
Otelixizumab dramatically reduces surface CD3 in blood and mucosal T cells.
We aimed to use concentrations of otelixizumab which caused internalization of surface CD3. With one million blood T cells, a concentration of 1μg/ml otelixizumab reduced CD3 sites from around 200,000 per cell to < 5,000 ( Fig 1A) . This effect persisted for 24h.
Otelixizumab caused the internalization of surface CD3 as well as disappearance of the αβ T cell receptor from the cell surface. Otelixizumab bound to CD3 blocked the binding of all available anti-TCR and anti-CD3 detection antibodies we have tested. As a consequence down-modulation of the CD3/TCR complex could only be measured by detection of bound otelixizumab with secondary detection antibodies. Downmodulation was evident after 4h (data not shown) and by 24h less than 50% of CD3/TCR molecules remained ( Fig 1A) . By day 4 almost 90% of the complexes had been internalized (data not shown). When biopsies from UC patients were cultured with 1µg/ml otelixizumab for 16h, rapidly dispersed without collagenase treatment between M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 11 two glass slides and incubated with FITC-anti-CD3, CD3 expression was greatly reduced on the cells from biopsies treated with otelixizumab. Strong CD3 expression was observed in cells isolated from biopsies treated with a control IgG ( Fig 1B) .
Otelixizumab is non-mitogenic and does not affect cell viability
T cells in both normal and inflamed human gut are in an activated state 10 , therefore the first experiments were designed to ensure that otelixizumab was neither mitogenic nor increased pro-inflammatory cytokine production by normal and IBD lamina propria mononuclear cells (LPMC). The rat YTH12.5 antibody, from which otelixizumab was derived, induced proliferation of T cells from normal human gut and from IBD mucosa. In contrast, otelixizumab was non-mitogenic, even in the presence of anti-CD28 ( Fig 1C) . In terms of cytokine production, YTH12.5 induced high levels of IFN-γ and IL-17A, both being important cytokines in IBD 25 , by both normal and IBD LPMC.
While there was some spontaneous IFN-γ and IL-17A production by IBD LPMC, cytokine production was reduced by otelixizumab ( Fig 1D) . Crohn's disease and control LPMCs were next cultured with plate-bound anti-CD3 Ab and anti-CD28 Ab in the culture medium. When otelixizumab was added at the onset of the cultures, IFN-γ and IL-17A production were significantly reduced. We also added otelixizumab after 16h to αCD3/CD28 stimulated LPMC. IFN-γ and IL-17A concentrations were reduced, but significance was only reached for control LPMCs (Fig 1E) . To test if otelixizumab treatment can reduce the stimulatory capacity of a subsequent YTH12.5 treatment, we
cultured LPMCs from normal and inflamed mucosa for 3h with otelixizumab, changed the medium, then added YTH12.5 for 21h. Pre-treatment with otelixizumab before YTH12.5 was added strongly diminished IFN-γ production by LPMCs. We observed that LPMCs pre-treated with YTH for 3h, then cultured with otelixizumab show a reduced IFN-γ response (Fig 1E, for IL-17A and IL-2 data see supplementary figure S1).
We determined if the inhibitory effects of otelixizumab were due to T cell death since an earlier in vitro study had indicated that the anti-CD3 antibody visilizumab rapidly induced apoptosis in gut T cells in IBD 9 . LPMCs were cultured with otelixizumab for 48h and stained with annexin V and propidium iodide. Otelixizumab at concentrations of up to 10μg/ml did not increase the number of apoptotic or dead cells in LPMCs from healthy gut or from CD and UC mucosa (Fig 1F) . Crohn's disease and UC LPMCs were more resistant to cell death than cells from healthy colon, confirming a previous study 26 .
Otelixizumab decreases proinflammatory cytokine production in inflamed mucosa
We next examined T cell responses in CD and UC mucosal biopsies cultured ex vivo. Otelixizumab reduced the concentrations of IFN-γ and IL-17A in CD and UC explant culture supernatants compared to the IgG control (Fig 2A) . The transcription factors Tbet and RORγT, the main regulators of IFN-γ and IL17 expression, respectively, were also reduced in CD explants treated with otelixizumab ( Fig 2B) . Supernatants of inflamed CD and UC explants were further subjected to a protein array to measures relative levels of The individual values are listed in supplementary table SII and III. Otelixizumab significantly increased the levels of IL-10 in IBD mucosa supernatants (supplementary tables II and III).
Otelixizumab reduces phosphorylation in IBD tissue to levels observed in healthy mucosa
Because phosphorylation of receptors and signaling molecules is an important mechanism for cells to respond to inflammation and other extracellular stimuli, we analysed the phosphorylation status of 39 receptor tyrosine kinases and signaling (Fig 3A, B) . There was variation between individual patients, especially in Crohn's disease, probably reflecting the patchy nature of the lesions. Average intensity values of phospho-proteins of IgG-treated vs. otelixizumabtreated samples were significantly different for CD and UC.
When phosphorylation status was measured in lysates of CD mucosal explants cultured with IgG for 48h, the strong level of phosphorylation was maintained, indicating the continuing persistence of the inflammatory process ex vivo ( Fig 3C showing single representative cases). Addition of otelixizumab to CD explants for 48h strongly reduced the phosphorylation of the majority of kinases (green bars in Fig 3C) .
Similar results were observed for UC explants cultured with IgG or otelixizumab for 48h (green bars in Fig 3C) . By 48h, the phosphorylation status of IBD biopsies cultured with otelixizumab had returned to about the same level as fresh normal mucosa. Notably, otelixizumab strongly inhibited phospho-proteins associated with T cell receptor signaling. 
Otelixizumab's effects are dependent on interleukin-10
Next, we focused on the role of IL-10 since in the array it was the only cytokine which increased with otelixizumab treatment. Supernatants of IBD LPMCs and explants cultured with otelixizumab showed increased IL-10 concentrations ( Fig 4A) . Biopsies of inflamed mucosa cultured with otelixizumab had higher relative IL-10 mRNA expression than the IgG treated biopsies as measured by RT-PCR ( Fig 4A) . When CD explants were cultured with otelixizumab and IL-10-neutralizing Ab, the IFN-γ concentration exceeded basal levels ( Fig 4B) . Unstimulated Crohn's disease LPMCs cultured with otelixizumab showed reduced intracellular IFN-γ and increased intracellular IL-10 ( Fig 4C) . We next determined if the reduction in the phospho-protein profile in IBD mucosa cultured exvivo with otelixizumab was IL-10-dependent. Consistent with our earlier experiments, otelixizumab treatment reduced the phosphorylation levels in CD explants ; supplementary table VII) . We confirmed the importance of IL-10 in our explant culture system by adding exogenous IL-10 to CD biopsies. IFN-γ and IL-17A levels were reduced in cultures treated with IL-10 ( Fig 4F) .
Discussion
Our results show that otelixizumab is profoundly anti-inflammatory when added to IBD LPMC and mucosal tissues from IBD patients. We must emphasize that this study was designed to show proof of principal that tolerising anti-CD3 antibodies have effects on T cells in inflamed tissue, and did not attempt to address why visilizumab, another tolerising anti-CD3 antibody, was not effective in ulcerative colitis in a randomized placebo controlled study 13 . We were well aware of the issues regarding the potential effects of dose of anti-CD3 antibodies and so we chose a dose of 1µg/ml for most of our studies since at this dose there was almost complete internalization of surface CD3 in blood T cells and in T cells in biopsies. The functional effects of otelixizumab were evidenced by the broad down-regulatory effects on pro-inflammatory cytokine and chemokine production, and even more remarkably, the reduction in phospho-protein levels in pathways unrelated to immune cells. For example, TrkA and TrkB are receptors for nerve growth factor and neurotrophins, ephrin receptors are involved in cell migration in many cell types, FGF receptors are involved in angiogenesis and wound healing, and HER2, HER3 and EGFR are involved in epithelial renewal. Since we can be M A N U S C R I P T
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completely sure otelixizumab only targets T cells, these data show that T cell activation drives these myriad increased signaling pathways in IBD.
We also show that otelixizumab increases IL-10 production by IBD biopsies and that the inhibitory effects of otelixizumab on phospho-protein reduction are IL-10 dependent. This is very similar to previous studies where patients with type I diabetes treated with a tolerising anti-CD3 antibody showed increases in serum IL-10, and activation of blood T cells also increased IL-10 production 27 . The new data that we present here show that the same effect occurs in activated T cells in tissues. It is very well established that IL-10 is a potent inhibitor of antigen presentation and the fact that we were able to show that otelixizumab reduced phosphorylated Lck and Zap70 in explants is consistent with both a decrease in antigen presentation and a loss of TcR signaling caused by the internalization of the TcR/CD3 complex. However, we must emphasize that we do not know if there is some signaling when otelixizumab binds to the CD3/TcR complex which delivers a signal to the T cell to shut down proinflammatory cytokines and produce IL-10, similar to the effects of anti-CD46 and anti-CD55 28, 29 .
An obvious question is whether otelixizumab is activating nascent IL-10 secreting regulatory T cells or whether it is driving Th1 or Th17 cells to produce IL-10. Our intracellular staining suggests the latter. However, we did examine if otelixizumab increased the number of CD4+, CD25+, FoxP3+ cells (Supplementary Figure 1) , and indeed this was the case. Further studies are needed to define exactly the pathways by which otelixizumab is having such powerful effects and importantly, whether the effects
we have identified here are seen at lower doses of antibody. Although systemic and mucosal delivery of IL-10 for IBD therapy failed 30, 31 , our study does re-inforce the important role of IL-10 in controlling inflammation in the human gut, and is consistent with reports on children with mutations in IL-10R who develop severe gut inflammation 32, 33 . In addition, studies in humanized mice have shown that treatment with the tolerising anti-CD3 antibody teplizumab induces T cells which home to the gut and secrete IL-10 34 . This study, however, was markedly different to ours because we investigated resident cells in human tissues.
Our present work also builds on animal models of inflammatory disease where anti-CD3 antibodies have proved to be beneficial. For example, in mouse models of systemic lupus erythematosus, nasal and oral administration of anti-CD3 antibody results in decreased numbers of IL17+ follicular T helper cells and an increase in IL10producing CD4+CD25+ T cells 35, 36 . Likewise, intravenous administration of anti-CD3 antibodies in murine experimental autoimmune encephalomyelitis (EAE) is helpful by the induction of regulatory T cells 37 ; and intraperitoneal treatment with an Fcengineered anti-CD3 antibody showed beneficial effects with regard to symptoms, cytokine levels and T cell numbers in EAE 38 .
We appreciate that a limitation of our study was the inability to track the fate and responsiveness of mucosal T cells treated with otelixizumab for prolonged periods of time because of the need to activate T cells in long-term culture to prevent cell death.
Also, the often limited availability of biopsies and surgical specimens prevented us from working with a larger number of cases. Further, we used only one dose of antibody
throughout our study. Therefore the focus of future studies will be to evaluate the effect of different otelixizumab doses on mucosal T cells as the issue of the optimal anti-CD3 in patients dose remains. For example, with regard to the failed clinical studies with visilizumab, it is not at all clear that 5 µg/kg for two days is a high enough dose to drive the internalization of the TcR/CD3 complex on all T cells in the tissues 11, 12 . Our in vitro studies had on the other hand the advantage that we could interrogate closely how otelixizumab affects cytokines and phosphorylation patterns in the inflamed mucosa;
something which would be difficult to do during a clinical trial.
In conclusion, we show here by various experimental approaches that the anti-CD3 antibody otelixizumab dampens inflammation in human tissue by a mechanism involving the induction of IL-10. Overall, we consider it premature to think tolerising anti-CD3 antibodies may not be a potential therapy for IBD on the basis of the previously failed clinical studies. Since otelixizumab can be given safely at much higher doses than other anti-CD3 antibodies, consideration should be given as to whether a clinical trial of this particular antibody in IBD may be justified. IL32alpha  IL27  IL23  IL25  IL17  IL16  IL13  IL12 p70  IL10  IL8  IL6  IL5  IL4  IL2  IL1ra  IL1beta  IL1alpha  IFNg  sICAM- 
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Supplementary Table I
Patient and disease characteristics of the CD and UC patients recruited for this study.
Supplementary Table II
Relative cytokine values that were measured in the explant supernatants by protein array.
Shown are the relative pixel intensities of the dots on the array (mean of duplicates per analyte). Explants of six Crohn's disease patients had been cultured for 16h with IgG or otelixizumab. Shown is also the table used for statistical testing.
Supplementary Table III
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Shown are the relative pixel intensities of the dots on the array (mean of dublicates per analyte). Explants of six ulcerative colitis patients had been cultured for 16h with IgG or otelixizumab. Shown is also the table used for statistical testing.
Supplementary Table IV
Relative phosphorylation levels that were measured in the explant lysates by phospho-protein array. Analysed were four healthy colon specimens, seven inflamed CD and six inflamed UC specimens. Specimens were immediately snap-frozen and untreated. Shown is also the table used for statistical testing.
Supplementary Table V
Relative phosphorylation levels that were measured in the explant lysates by phospho-protein array. Explants of six Crohn's disease patients had been cultured for 48h with IgG or otelixizumab. Lysates were subjected to the phospho-protein array and relative intensities of the dots (in duplicates) were measured. Shown is also the table used for statistical testing.
Supplementary Table VI
Relative phosphorylation levels that were measured in the explant lysates by phospho-protein array. Explants of six ulcerative colitis patients had been cultured for 48h with IgG or otelixizumab. Lysates were subjected to the phospho-protein array and relative intensities of the dots (in duplicates) were measured. Shown is also the table used for statistical testing.
Supplementary Table VII
Relative phosphorylation levels that were measured in the explant lysates by phospho-protein array. Explants of five Crohn's disease patients had been cultured for 24h as indicated. Lysates
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were subjected to the phospho-protein array and relative intensities of the dots (in duplicates)
were measured. Shown is also the table used for statistical testing.
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